Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Infarction

ClinicalTrials.gov lists 3,391 trials for Infarction or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 64.

MeSH D007238 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 65 Phase 1/2 Phase 1/2 54 Phase 2 Phase 2 225 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 294 Phase 4 Phase 4 375 Not applicable Not applicable 1,002 Observational Observational 1,311 Phase 1 Phase 1 65 Phase 1/2 Phase 1/2 54 Phase 2 Phase 2 225 Phase 2/3 Phase 2/3 62 Phase 3 Phase 3 294 Phase 4 Phase 4 375 Not applicable Not applicable 1,002 Observational Observational 1,311

Trials per phase (log scale)

1 more section with rows

56 of the 3,391 trials are tagged with Infarction itself; the rest are tagged with a narrower condition beneath it.

Get the Infarction report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Infarction trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 187

1990: 2 trials (Observational 2) 1991: 7 trials (Observational 7) 1992: 6 trials (Observational 2, Phase 3 4) 1993: 4 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1) 1994: 9 trials (Observational 7, Phase 3 2) 1995: 12 trials (Observational 9, Phase 3 3) 1996: 2 trials (Phase 4 1, Phase 3 1) 1997: 9 trials (Observational 6, Not applicable 1, Phase 3 2) 1998: 12 trials (Observational 9, Phase 3 3) 1999: 15 trials (Observational 8, Phase 4 3, Phase 3 3, Phase 2 1) 2000: 14 trials (Observational 7, Not applicable 3, Phase 3 4) 2001: 27 trials (Observational 13, Not applicable 4, Phase 4 4, Phase 3 5, Phase 2/3 1) 2002: 26 trials (Observational 7, Not applicable 3, Phase 4 4, Phase 3 8, Phase 2 2, Phase 1 2) 2003: 65 trials (Observational 23, Not applicable 9, Phase 4 9, Phase 3 12, Phase 2/3 2, Phase 2 7, Phase 1/2 2, Phase 1 1) 2004: 51 trials (Observational 17, Not applicable 6, Phase 4 12, Phase 3 7, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 1) 2005: 74 trials (Observational 16, Not applicable 11, Phase 4 15, Phase 3 15, Phase 2/3 3, Phase 2 6, Phase 1/2 3, Phase 1 5) 2006: 89 trials (Observational 25, Not applicable 12, Phase 4 19, Phase 3 13, Phase 2/3 3, Phase 2 11, Phase 1 6) 2007: 92 trials (Observational 32, Not applicable 17, Phase 4 16, Phase 3 6, Phase 2/3 5, Phase 2 10, Phase 1/2 3, Phase 1 3) 2008: 85 trials (Observational 21, Not applicable 15, Phase 4 7, Phase 3 14, Phase 2/3 9, Phase 2 11, Phase 1/2 4, Phase 1 4) 2009: 97 trials (Observational 24, Not applicable 25, Phase 4 18, Phase 3 7, Phase 2/3 5, Phase 2 15, Phase 1/2 1, Phase 1 2) 2010: 106 trials (Observational 45, Not applicable 23, Phase 4 12, Phase 3 13, Phase 2/3 1, Phase 2 6, Phase 1/2 4, Phase 1 2) 2011: 134 trials (Observational 44, Not applicable 32, Phase 4 21, Phase 3 11, Phase 2/3 4, Phase 2 12, Phase 1/2 7, Phase 1 3) 2012: 116 trials (Observational 45, Not applicable 35, Phase 4 13, Phase 3 8, Phase 2 10, Phase 1/2 2, Phase 1 3) 2013: 116 trials (Observational 41, Not applicable 38, Phase 4 11, Phase 3 12, Phase 2/3 1, Phase 2 9, Phase 1/2 1, Phase 1 3) 2014: 143 trials (Observational 59, Not applicable 38, Phase 4 24, Phase 3 10, Phase 2/3 2, Phase 2 9, Phase 1 1) 2015: 160 trials (Observational 60, Not applicable 43, Phase 4 23, Phase 3 9, Phase 2/3 3, Phase 2 11, Phase 1/2 6, Phase 1 5) 2016: 142 trials (Observational 50, Not applicable 57, Phase 4 16, Phase 3 6, Phase 2/3 2, Phase 2 7, Phase 1/2 4) 2017: 161 trials (Observational 62, Not applicable 58, Phase 4 23, Phase 3 4, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 2) 2018: 172 trials (Observational 76, Not applicable 55, Phase 4 21, Phase 3 8, Phase 2/3 3, Phase 2 8, Phase 1/2 1) 2019: 162 trials (Observational 76, Not applicable 53, Phase 4 10, Phase 3 10, Phase 2/3 1, Phase 2 8, Phase 1/2 1, Phase 1 3) 2020: 169 trials (Observational 78, Not applicable 56, Phase 4 12, Phase 3 9, Phase 2/3 1, Phase 2 10, Phase 1/2 2, Phase 1 1) 2021: 181 trials (Observational 71, Not applicable 60, Phase 4 18, Phase 3 17, Phase 2/3 3, Phase 2 8, Phase 1/2 4) 2022: 179 trials (Observational 77, Not applicable 67, Phase 4 15, Phase 3 6, Phase 2 9, Phase 1/2 2, Phase 1 3) 2023: 187 trials (Observational 74, Not applicable 83, Phase 4 11, Phase 3 9, Phase 2 7, Phase 1 3) 2024: 164 trials (Observational 68, Not applicable 65, Phase 4 6, Phase 3 10, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 3) 2025: 173 trials (Observational 67, Not applicable 61, Phase 4 14, Phase 3 12, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 171
2025 173
2024 164
2023 187
2022 179
2021 181
2020 169
2019 162
2018 172
2017 161

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 190 trials starting in 2026 and about 180 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 253 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 1,835 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Infarction trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 65
Phase 1/2 54
Phase 2 225
Phase 2/3 62
Phase 3 294
Phase 4 375
Not applicable 1,002
Observational 1,311
Expanded access 3

How many Infarction trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 167
Recruiting 415
Enrolling by invitation 21
Active, not recruiting 109
Available 2

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Infarction trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 64
AstraZeneca 18

Which drugs are being tested for Infarction? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 22
Tenecteplase 17
Abciximab 16
BMS-512148 15
Rivaroxaban 15

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ticagrelor (Brilique) 90 63
Clopidogrel 75 56
EC Aspirin 53
Prasugel 26
Colchicines 22

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Infarction trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Other 16,735 7
MVE 6,060 1
Pneumonia 3,002 60
Hospitalization 1,855 2
Angina pectoris 1,645 41

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Infarction? (87)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochimica et biophysica acta. Molecular basis of disease 2020 Yes
Cervical Cord Infarction Caused by Dissection of the Intracranial Segment of the Vertebral Artery. Internal medicine (Tokyo, Japan) 2018 Yes
"Rusty Hearts": Is It Time to Rethink Iron Chelation Therapies in Post-Myocardial-Infarction Setting? Circulation. Cardiovascular imaging 2016 Yes
Mortality after acute primary mesenteric infarction: a systematic review and meta-analysis of observational studies. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2015 Yes
Vein visualization: patient characteristic factors and efficacy of a new infrared vein finder technology. British journal of anaesthesia 2013 Yes

Showing 5 of 87 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages